GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

68.74 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting

March 13, 2025

From GeneDx

Via Business Wire

GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

March 13, 2025

From GeneDx

Via Business Wire

SPY Trying To Find A Floor At The 200 SMA; One New Swing ↗

March 08, 2025

In this video lesson I review the day-one of a new rally attempt in the overall market, discuss my new swing trade in a cyber-security leader, and review my tier-one long-term portfolio purchases in my...

Via Talk Markets

Topics Stocks / Equities

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication

March 04, 2025

From GeneDx

Via Business Wire

Powerful UnR Session As All Four Market Indices Lockstep Rally Into The Close; Bear Trap Set? ↗

February 28, 2025

In this video lesson, I review the overall market, the recent bearish sentiment, and one new swing trade idea for Monday's session.

Via Talk Markets

Topics Stocks / Equities

Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols

February 24, 2025

From GeneDx

Via Business Wire

Top Biotech GeneDx Catapults 42% After Obliterating Earnings Forecasts ↗

February 18, 2025

GeneDx stock catapulted more than 40% on Tuesday after the top-notch biotech smashed fourth-quarter expectations.

Via Investor's Business Daily

Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings ↗

February 18, 2025

Via Benzinga

Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗

February 18, 2025

Via Benzinga

US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday? ↗

February 18, 2025

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

February 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 18, 2025

Via Benzinga

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

February 18, 2025

From GeneDx

Via Business Wire

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

Earnings Scheduled For February 18, 2025 ↗

February 18, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 14, 2025

Via Benzinga

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

February 13, 2025

From GeneDx

Via Business Wire

GeneDx to Participate in 45th Annual TD Cowen Health Care Conference

February 12, 2025

From GeneDx

Via Business Wire

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

February 10, 2025

From GeneDx

Via Business Wire

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

January 28, 2025

From GeneDx

Via Business Wire

GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play

January 27, 2025

Saying shares of GeneDx skyrocketed in 2024 may be an understatement. As a leader in its market, upside is still a legitimate possibility for this name.

Via MarketBeat

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 17, 2025

From GeneDx

Via Business Wire

Stocks Moving Lower Despite Encouraging Inflation Data ↗

January 14, 2025

Via Talk Markets

Topics Economy Stocks / Equities

GeneDx Announces Preliminary 2024 Financial Results

January 13, 2025

From GeneDx

Via Business Wire

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

January 09, 2025

From GeneDx

Via Business Wire

I’m Not Worried About This Pullback ↗

January 08, 2025

Stocks gave back all of Monday’s gains and then some today. Monday’s panic buyers were mercilessly punished for going nuts during the spree.

Via Talk Markets

Topics Cryptocurrencies Stocks / Equities

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

January 08, 2025

From GeneDx

Via Business Wire

IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development ↗

January 06, 2025

GeneDx provides whole and exome gene sequencing to identify rare diseases.

Via Investor's Business Daily

Topics Artificial Intelligence

Focus On High Cash Flow Companies. You Are The Company You Keep. ↗

January 05, 2025

There are too many stocks acting well to expect a bear market right now.

Via Talk Markets

Topics Stocks / Equities

Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly ↗

January 04, 2025

Energy plays, a biotech and a brokerage also are flashing buy signals or setting up.

Via Investor's Business Daily

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.